About BioSpecifics

BioSpecifics is a biopharmaceutical company that originated and continues to develop collagenase-based therapies. Collagenases are naturally occurring enzymes responsible for the breakdown of collagen. Collagen is the main structural protein in the extracellular matrix in the various connective tissues of the body and is the most abundant protein in mammals. Local accumulations of excess collagen are associated with a number of medical conditions. We have developed a first-in-class collagenase-based product collagenase clostridium histolyticum (CCH) marketed in the U.S. as XIAFLEX® by our partner Endo Pharmaceuticals for the treatment of Dupuytren's contracture and Peyronie's disease.

In addition to investing in the development of several potential new indications for its collagenase-based technology, BioSpecifics is seeking to partner with companies that possess novel therapeutics that will deliver meaningful benefits for patients.

About BioSpecifics

Corporate Presentation

Pipeline

The CCH research and development pipeline includes several additional potential indications including adhesive capsulitis, plantar fibromatosis and uterine fibroids

Learn More